LO Ovral Related Published Studies
Well-designed clinical trials related to LO Ovral (Norgestrel / Ethinyl Estradiol)
A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. [2005.02]
Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. [2005.02]
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. [2005.01]
Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. [2004.11]
Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. [2004.06]
Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. [2004.02]
Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO. [2003.07]
Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. [2003.07]
The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. [2003.05]
Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. [2003.05]
Prospective evaluation of two stimulation protocols for low responders who were undergoing in vitro fertilization-embryo transfer. [2003.04]
Vitamin D receptor gene polymorphism and bone metabolism during low-dose oral contraceptive use in young women. [2003.01]
Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. [2003.01]
Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. [2003.01]
Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women. [2002.12]
The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 micro g ethinyl estradiol versus monophasic levonorgestrel/20 micro g ethinyl estradiol. [2002.09]
Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. [2002.09]
A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. [2002.05]
Effect of two oral contraceptives containing ethinylestradiol and levonorgestrel on serum and urinary surrogate markers of endothelial function. [2002.04]
Long-term effects of combined oral contraceptives on markers of endothelial function and lipids in healthy premenopausal women. [2002.03]
An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. [2002.03]
Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. [2002.02]
Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. [2002.01]
Effect of two oral contraceptives with different ethinyl estradiol and levonorgestrel concentrations on the urinary excretion of biochemical vasoactive markers. [2001.12]
The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. [2001.11]
A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. [2001.10]
A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. [2001.09]
Effects of two low-dose oral contraceptives containing ethinylestradiol and either desogestrel or levonorgestrel on serum lipids and lipoproteins with particular regard to LDL size. [2001.07]
Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. [2001.07]
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. [2001.06]
Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. [2001.06]
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. [2000.07]
Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. [2000.07]
Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. [2000.07]
Comparison of ovarian follicular activity during treatment with a monthly injectable contraceptive and a low-dose oral contraceptive. [2000.03]
Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. [1999.12.11]
Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. [1999.12]
Effect of low-dose oral contraceptives on androgenic markers and acne. [1999.11]
A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 microg levonorgestrel with 20 microg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. [1999.11]
Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. [1999.08]
A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. [1999.06]
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. [1999.06]
Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles. [1999.05]
Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). [1999.03]
Levonorgestrel versus the "Yuzpe" regimen. New choices in emergency contraception. [1999.03]
Short-term treatment with levonorgestrel does not antagonize the ethinyl estradiol-induced increase of uterine blood flow in postmenopausal women. [1997.09]
Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive. [1997.04]
Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin). [1996.06]
Changes in androgens during treatment with four low-dose contraceptives. [1996.03]
Ovarian activity suppression by two different low-dose triphasic oral contraceptives. [1995.12]
Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study. [1995.09]
Ovarian function during low-dose oral contraceptive use. [1995.06]
Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives. [1995]
Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. [1994.03]
Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids. [1993.10]
A comparative study of two low-dose combined oral contraceptives: results from a multicenter trial. [1993.08]
A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives. [1993.06]
Effect of four combined oral contraceptives on blood pressure in the pill-free interval. [1993.04]
A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. [1993.03]
A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study. [1993.01]
Effects of two low-dose oral contraceptives on erythrocyte superoxide dismutase, catalase and glutathione peroxidase activities. [1993]
Comparative assessment of two low-dose oral contraceptives, Lo-Femenal and Lo-Estrin, in Mexican women. [1992.12]
Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. [1992.11]
Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. [1992.11]
Lipid and biochemical changes after low-dose oral contraception. [1992.09]
A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. [1992.06]
Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets. [1992.02]
Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. [1992.02]
Long-term profile of a new progestin. [1992]
A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. [1992]
Effect of long-term triphasic oral contraceptive use on glucose tolerance and insulin secretion. [1991.07]
Intrasubject variability in the pharmacokinetics of ethynyloestradiol. [1991.06]
A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors. [1991.01]
Effect of low-dose oral contraceptives on carbohydrate and lipid metabolism in women with recent gestational diabetes: results of a controlled, randomized, prospective study. [1990.12]
Low-dose oral contraceptives lower plasma levels of apolipoprotein E. [1990.11]
A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. [1990.11]
Cycle control on low-dose oral contraceptives: a comparative trial. [1990.09]
Two-year carbohydrate metabolism studies in women using a norethindrone or levonorgestrel triphasic oral contraceptive. [1990.09]
Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. [1990.04]
A comparative study of three oral contraceptives in Ibadan: Norinyl 1/35, Lo-Ovral and Noriday 1/50. [1990.03]
Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. [1990.01]
Hemorheological effects of oral contraceptives. [1989.11]
Bleeding patterns with low-dose, monophasic oral contraceptives. [1989.09]
Effects of seven low-dose combined contraceptives on vitamin B6 status. [1989.09]
Haemorheological consequences of oestrogen and progestogen therapy. [1989.08]
Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization. [1989.06]
Metabolic effects of three new low-dose pills: a six-month experience. [1989.06]
Effects of three types of combined O.C. pills on blood coagulation, fibrinolysis and platelet function. [1989.04]
Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinylestradiol and gonane progestins. [1988.06]
Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. [1987.10]
The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. [1987.09]
ICMR Task Force Study on hormonal contraception. Transfer of norethisterone (NET) and levonorgestrel (LNG) from a single tablet into the infant's circulation through the mother's milk. [1987.06]
Effects of three low-dose oral contraceptive formulations on lipid metabolism. [1987]
Clinical and metabolic effects of gestodene and levonorgestrel. [1987]
Blood coagulation with a combination pill containing gestodene and ethinyl estradiol. [1987]
The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. [1986.10]
Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. [1985.04]
A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. [1985.02]
Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. [1984]
Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. [1983.05]
[The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)] [1981.10.16]
|
